An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
Now Recruiting: Moores Cancer Center (MCC), Associate Director for Community Outreach and Engagement (AD COE)
MCC is now seeking candidates from UC San Diego, San Diego State University (SDSU), and/or La Jolla Institute for Immunology (LJI) for the position of MCC AD COE.
The principal role of the MCC AD COE will be to foster bidirectional communication between MCC members and community stakeholders in our catchment area and beyond. This communication plays a central role in MCC research efforts. As such, the MCC AD COE works directly with the MCC Community Advisory Board, COE staff, community collaborators, and MCC members. The MCC AD COE will provide leadership to execute a focused mission, vision, and strategy for COE that aligns with not only the MCC Strategic Plan, but also COE-related initiatives of UC San Diego Health, UC San Diego Health Sciences, LJI, SDSU, and the larger UC San Diego campus. The MCC AD COE is charged with promoting and advancing innovative ideas, programs, and initiatives for outreach, engagement, and bidirectional communication with the San Diego community.
Any interested faculty members are encouraged to submit (1) a letter of interest that includes a vision for the position and (2) a current CV to Xochitl Villanueva at xvillanueva@health.ucsd.edu by Tuesday, April 18, 2023.
|
|
|
Join the MCC Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
| Pharmacology Seminar Series
T Cells at the Heart of Cardiac Fibrosis
Tuesday, April 11, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
Zoom Link
Pilar Alcaide, Ph.D.
Director, Immunology Graduate Program
Assistant Dean, Faculty Development
Kenneth and JoAnn G. Wellner Professor
Associate Professor and Vice Chair
Department of Immunology
Tufts University, School of Medicine
Hosted by Joan Heller Brown, Ph.D.
|
|
|
| SFG Cross-Lab Meeting
Multi-level Dissection of Breast Cancer
Wednesday, April 12, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
Zoom Link
William Kim, Ph.D.
Assistant Professor
Division of Genomics and Precision Medicine
UC San Diego, School of Medicine
Member, MCC
|
|
|
| Pharmacology Seminar Series
A Newfound Mechanism of Metabolite Regulation over Cell Cycle and Proliferation
Tuesday, April 18, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
Zoom Link
Edward T. Chouchani, Ph.D.
Associate Professor of Cell Biology
Harvard Medical School
Associate Professor of Cancer Biology
Dana-Farber Cancer Institute
Hosted by Åsa Gustafsson, Ph.D.
|
|
|
| Solid Tumor Therapeutics Seminar
Unconventional Signaling of CD28 and CTLA4: When Their Ligands Get on T Cells
Friday, April 21, 2023 from 12:00 to 12:45 p.m. PT
MCC Comer Commons
Zoom Link
Enfu Hui, Ph.D.
Associate Professor
Department of Cell and Developmental Biology
UC San Diego, School of Biological Sciences
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC Cancer Research, Training, and Education Coordination (CRTEC). These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Administrative Supplement Announcement from the NCI Division of Cancer Control and Population Sciences (DCCPS)
NCI has released three separate Notice of Special Interest (NOSI) administrative supplement opportunities that are open to current awardees of numerous active NCI-funded grants. Please see the eligibility for each supplement in the links below.
|
-
Digital Health and PPC across the Cancer Control Continuum. This NOSI will support studies that seek to better understand (1) the effects of digital health tools/interventions on patient-provider communication, and/or (2) how patient-provider communication influences the relationship between digital health tools/interventions and cancer prevention and control outcomes (e.g., care quality, health behavior, and health equity. Studies that address under-resourced settings and underserved populations are of particular interest. More information can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-041.html
-
Health Policy Research in Cancer Prevention and Control. This NOSI will support studies that (1) generate new or utilize secondary data that operationalize policies hypothesized to affect cancer control at the geographic, provider, patient, and/or temporal level, (2) examine the effects of existing policies and/or simulate the potential effects of new policies, with an emphasis on understanding health disparities by examining differential impacts on disadvantaged groups, and (3) identify effective community-engaged strategies for dissemination or implementation of evidence to inform policy making. More information can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-044.html
-
Polygenic Risk Scores for Cancer Risk Assessment. This NOSI will support studies that (1) identify the potential for clinical utility (CU) of cancer-site specific polygenic risk scores (PRS) for cancer risk assessment, (2) describe the state of the science in terms of cancer-site specific PRS development and evaluation, (3) assess the current evidence for efficacy and/or effectiveness of PRS CU and potential benefits and harms of their clinical use (e.g., consideration of available screening and prevention interventions based on risk), and (4) propose criteria and optimal study designs and methods for which PRS are candidates for evaluation of CU through clinical trials. More information can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-046.html
|
Although more than one application per institution can be submitted, only one supplement application can be submitted per parent award. Please inform Divya Subramonian Ph.D. at dsubramonian@health.ucsd.edu if you plan to apply for any of these supplements.
NCI Application Deadline: Friday, April 21, 2023 by 5:00 p.m.
|
| |
2023 Bayer-Prostrate Cancer Foundation (PCF) Health Equity Research Awards for Health Equity Implementation Research for Patients with Prostate Cancer
Award provides up to a total of $200K/year per team over 2 years. Approximately $500K is designated for this award mechanism.
PCF and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Health Equity Research Awards to fund novel health equity implementation research projects, with the goal of reducing racial and ethnic disparities in the diagnosis and treatment of advanced prostate cancer. Proposals will be funded, depending on their level of innovation. Both PCF and Bayer seek high-risk, currently unfunded projects from only academic institutions in the United States.
LOI Submission Deadline: Friday, May 5, 2023 at 3:00 p.m. ET
Application Submission Deadline: Monday, July 10, 2023 at 3:00 p.m. ET
|
|
|
2023 Bayer-PCF Darolutamide Challenge Awards for Clinical Investigations on Novel Uses of Darolutamide in Prostate Cancer
Award provides up to a total of $1M per team. Approximately $3M is designated for this award mechanism.
PCF and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Challenge Awards to fund novel investigator-initiated clinical investigations that address correlative research for darolutamide in prostate cancer. Proposals will be funded, depending on their level of innovation. PCF and Bayer seek high-risk, currently unfunded projects from only academic institutions in the United States.
Application Submission Deadline: Monday, June 5, 2023 at 3:00 p.m. ET
|
|
|
Robert A. Winn, Diversity in Clinical Trials Career Development Award (Winn CDA) for Early-Stage Investigator Physicians
The Winn CDA provides $120K/year for 2 years to protect 40% of the awardee's work time for program participation.
The Winn CDA is a 2-year program designed to support the career development of early-stage investigator (ESI) physicians (as defined by NIH) who are underrepresented in medicine (URM) or who have a demonstrated commitment to increasing diversity in clinical research. The program prepares URM ESI physicians to become independent clinical trial investigators engaged in advancing health equity through their research and mentoring. The goal of the Winn CDA is to transform the clinical research landscape by building and strengthening partnerships between clinical investigators and the communities in which their patients reside to ultimately engage a patient population that mirrors the epidemiology of the disease studied.
|
Deadline: Friday, May 12, 2023
|
|
|
Department of Defense (DOD), Ovarian Cancer Research Program (OCRP), Clinical Trial Award (CTA)
The DOD Congressionally Directed Medical Research Program (CDMRP) will allot approximately $6.4M to fund one to three CTA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTA should not exceed $2.0M.
The DOD CDMRP OCRP CTA supports the rapid implementation of clinical trials with the potential to heavily influence the treatment or management of ovarian cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, and Phase 0 trials) to demonstrate the feasibility or inform the design of more advanced trials to large-scale trials to determine efficacy in relevant patient populations.
Required Pre-Application Submission Deadline: Friday, May 26, 2023
|
|
|
DOD OCRP Clinical Translational Research Award (CTRA)
The DOD CDMRP will allot approximately $3.2M to fund one to two CTRA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTRA should not exceed $2.0M.
The DOD CDMRP OCRP CTRA supports correlative studies that are associated with a clinical trial (past, ongoing, or future) to correlate various factors (genetic, biochemical, environmental, and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis, or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. Although not all-inclusive, research proposed under this mechanism may entail initiation of a deeper molecular analysis of clinical samples, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis testing or may be designed to generate clinically annotated and molecularly characterized experimental platforms (e.g., tissue arrays and patient-derived models). The award may not be used to directly support a clinical trial.
Required Pre-Application Submission Deadline: Friday, May 26, 2023
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Notice of Special Interest (NOSI): Administrative Supplements for NCI Division of Cancer Biology (DCB) Research Programs
You may submit applications for this initiative using any of the 24 funding opportunity announcements (FOAs) listed on the website above or any reissues of these announcement through the expiration date of this notice.
Through this NOSI, current awardees of DCB-led programs can apply for supplemental funding to support collaborative research projects. DCB-led or DCB-co-led programs appropriate for this NOSI include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.
Deadline: April 20, 2023
|
|
|
National Partnerships to Promote Cancer Surveillance Standards and Support Data Quality and Operations of National Program of Cancer Registries (NPCR)
This Notice of Funding Opportunity (NOFO) will enable organizations with a long-standing history of contributing to population-based cancer surveillance to apply their strengths and experience to work in tandem on cancer surveillance data standards and processes relevant to NPCR data collection.
The NOFO will support three proposed project components, each of which will target a specific set of strategies.
|
-
Cancer Data Standards Integration (Component 1). The recipient of this award will (1) manage the overall coordination of data item development, vetting, and definitions to be included in North American data standards, (2) evaluate the alignment of NAACCR standards with current and emerging national healthcare data standards, and (3) educate NPCR registries on data collection and evaluation to support high-quality data and central cancer registry practice.
- Cancer Staging and Care Quality (Component 2). The recipient of this award will (1) bridge clinical expertise on TNM cancer staging and cancer quality care measurements with the cancer surveillance system operations, which include assessment and incorporation of shared data items into NPCR software, and (2) provide education to NPCR and registry staff.
-
Electronic Cancer Pathology and Laboratory Reporting (Component 3). The recipient of this award will (1) develop and maintain interoperable cancer pathology and biomarker reporting laboratories standards and (2) engage in demonstration projects to facilitate report into NPCR registries.
|
LOI Deadline: April 28, 2023
Application Deadline: June 1, 2023
|
|
|
Provision of Training and Technical Assistance to Enhance Comprehensive Cancer Control Outcomes
This multi-component NOFO will fund up to three recipients with national reach, cancer expertise, and capacity to provide training and technical assistance on multisectoral partnerships; policy, system, and environmental change approaches; health equity change; and social determinants of change approaches to National Comprehensive Cancer Control Program (NCCCP) recipients and cancer coalitions.
Deadline: May 8, 2023
|
|
|
NOSI: Administrative Supplement to Support Global Cancer Stigma Research
Applications can be submitted on a rolling basis between January 16, 2023 and May 21, 2023 at 5:00 p.m. local time of applicant organization for FY 2023 funding. Applications for this initiative must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
|
|
Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial Optional)
Application budgets may not exceed $250,000 in direct costs; maximum project length is 4 years.
Deadline: June 2, 2023
|
| Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
UG3: Application budgets may not exceed $250,000 in direct costs per year; maximum project period is 3 years.
UH3: Application budgets may not exceed $400,000 in direct costs per year; maximum project period is 2 years.
Deadline: June 30, 2023
|
| Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)
Application budgets should reflect the actual needs of the proposed project but must not exceed $700,000 in direct costs per year; maximum project period is 5 years.
Deadline: June 30, 2023
|
|
|
Department of Defense (DOD) Ovarian Cancer, Investigator-Initiated Research Award
Amounts from $300K to $800K; pre-application required; due date April 17, 2023.
Deadline: July 21, 2023
|
| DOD Lung Cancer Translational Research Award
Amounts from $375K to $1.2M; pre-application required; due dates May 2 and May 10, 2023.
Deadline: August 3, 2023
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
|
|
NOSI: Career Development Opportunities for Research within the Mission of the NCI Division of Cancer Prevention (DCP)
This NOSI applies to due dates on or after February 12, 2023 and subsequent receipt dates through November 13, 2024.
|
| NOSI: Technology Development for Cancer Control and Population Science Research.
This NOSI applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024.
|
| NOSI: Research on the Etiology, Early Detection, Screening, and Prevention of Early-Onset Colorectal Cancer
This NOSI applies to due dates on or after January 5, 2023 and subsequent receipt dates through July 2, 2025.
|
|
|
NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
A budget for direct costs of up to $50,000 per year may be requested; maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
The combined budget for direct costs for the 2-year maximum project period may not exceed $275,000; no more than $200,000 may be requested in any single year.
Deadline: Standard NIH deadlines apply
|
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
|
|
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are limited to $600,000 direct costs (excluding consortium F&A) per year; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| NOSI: Adaptive Biomaterials for Cancer Biology
This NOSI invites applications that propose the development of advanced biomaterials for use in fundamental cancer biology research and proposals incorporating the novel application of advanced biomaterials to address cancer biology research questions.
Deadline: Standard NIH deadlines apply
|
| Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
R01: Application budget is not limited; maximum project period is 5 years.
R21: Combined budget may not exceed $275,000; may not request more than $200,000 per year; maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
|
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
Postdoctoral Positions in Cancer Research
The laboratory of Dr. Thomas Kipps at MCC is seeking highly qualified and motivated postdoctoral fellows (scientists) to participate in state-of-the-art translational cancer research projects to investigate the genetics and immunology of cancer development and the generation of novel pharmacologic cancer therapeutics.
The Kipps laboratory investigates novel therapeutics for patients with leukemia and solid tumors. A particular focus of the laboratory is the function of onco-embryonic antigens, such as ROR1, which are selectively expressed by tumor cells and that contribute to malignant behavior. This involves the development and testing of novel agents that can target such antigens and/or their associated signaling pathways that contribute to the survival, growth, metastatic potential, and/or cancer stemness of neoplastic cells, even in the setting of conventional anti-cancer therapy. These studies can result in the development of more-effective therapies for patients with cancer.
Applicants for these postdoctoral positions must possess a Ph.D., strong analytical skills, proficiency in oral and written scientific presentations, and a demonstrated commitment to a career in cancer research.
These postdoctoral positions are offered preferably to candidates who have recently received their Ph.D. or have completed 3 years or less of post graduate education.
If interested, then submit a cover letter, curriculum vitae, statement of research interests, and the names and contact information of three references to Beth Lipski at elipski@ucsd.edu.
|
|
|
CRTEC Speed Mentoring Workshop
Thursday, April 13, 2023 from 12:00 p.m. to 1:00 p.m.
Lunch provided, starting at 11:30 a.m.
MCC, Comer Commons Conference Room
Two new speed mentors will be featured in April: Nicholas Lopez-Galvez, Ph.D., Assistant Professor at SDSU and expert in environmental health; Rebecca White, M.D., FACS, Associate Professor of Surgery and surgical oncologist at UC San Diego. In this 1-hour workshop, each each trainee (e.g., undergraduate, graduate, or medical student; postdoctoral fellow; resident; junior faculty member) will have the opportunity to speak directly with both mentors and receive advice on a variety of perspectives in a short amount of time. Sign up now because spaces are limited.
|
|
|
OncLive Institutional Perspectives in Cancer: Gynecologic Cancers
Monday, April 24, 2023 from 6:30 p.m. to 8:00 p.m.
Webinar Only
|
|
|
38th Annual Society for Thermal Medicine Meeting
April 23-27, 2023
Catamaran Resort Hotel, San Diego, CA
Visit the Society for Thermal Medicine website for programming, information, and registration.
|
|
|
NCI Virtual Workshop to Engage Multi-Cancer Detection (MCD) Assay Developers
Wednesday, May 3, 2023 from 1:00 p.m. to 5:00 p.m. ET
The NCI Division of Cancer Prevention is hosting a virtual workshop to explain a method of engagement for assay developers who are interested in having their assays considered for selection to the Vanguard study.
This interactive workshop is designed for multi-cancer detection (MCD) assay developers who are interested in participating in trials and studies to be run by a new Cancer Screening Research Network (CSRN) that is being established by NCI, which recognizes the importance of MCD assays and is interested in assessing their use as cancer screening tools. The CSRN is anticipated to start in January 2024, and its initial effort will be launching the Vanguard study (RFA-CA-23-020, RFA-CA-23-021, RFA-CA-23-022).
|
|
|
Structural and Functional Genomics (SFG) Program Retreat
Friday, May 5, 2023
MCC Goldberg Auditorium and Lobby
Breakfast and lunch will be provided.
|
|
|
Joseph Califano, M.D.
Director, MCC
Director, Gleiberman Head and Neck Cancer Center
Professor, Department of Otolaryngology/Head and Neck Surgery UC San Diego, School of Medicine
Co-Leader, MCC, SFG Program
|
| Jill P. Mesirov, Ph.D.
Associate Vice Chancellor for Computational Health Sciences
Professor, Department of Medicine
UC San Diego, School of Medicine
Co-Leader, MCC, SFG Program
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
SHARED RESOURCE SPOTLIGHT
|
|
|
MCC Tissue Technology Shared Resource (TTSR) Receives Accreditation from the College of American Pathologists (CAP)
The CAP Accreditation Committee has awarded accreditation to the MCC TTSR, based on results of a recent on-site inspection as part of CAP's Accreditation Programs.
TTSR Director, Alfredo Molinolo, M.D., Ph.D., was advised of this national recognition and congratulated for the excellence of the services being provided. The MCC TTSR lab is one of more than 8,000 CAP-accredited facilities worldwide.
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program.
During the CAP accreditation process, which is designed to ensure the highest standards of care for all laboratory patients, inspectors examine a given laboratory's records and quality control of procedures for the preceding 2 years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, peruse the CAP Annual Report: https://www.cap.org/
|
|
|
-
Eskander RN (CCP), Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023 MAR 27.
-
Crews LA (HEM), Ma W, Ladel L, Pham J, Balaian L, Steel SK, Mondala PK, Diep RH, Wu CN, Mason CN, van der Werf I, Oliver I, Reynoso E, Pineda G, Whisenant TC, Wentworth P, La Clair JJ, Jiang Q (HEM), Burkart MD, Jamieson CHM (HEM). Reversal of malignant ADAR1 splice isoform switching with rebecsinib. Cell Stem Cell. 2023 MAR 02.
-
Huh HD, Sub Y, Oh J, Kim YE, Lee JY, Kim HR, Lee S, Lee H, Pak S, Amos SE, Vahala D, Park JH, Shin JE, Park SY, Kim HS, Roh YH, Lee HW, Guan KL (CBS), Choi YS, Jeong J, Choi J, Roe JS, Gee HY, Park HW. Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination. Mol Cancer. 2023 MAR 30.
- Jang H, Li Y, Fung AA, Bagheri P, Hoang K, Skowronska-Krawczyk D, Chen X, Wu JY, Bintu B, Shi L (STT). Super-resolution SRS microscopy with A-PoD. Nat Methods. 2023 MAR 01.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to this newsletter, please make use of the newsletter submission form that is linked below. To submit to the newsletter submission form, you must be logged into Google with your UC San Diego email account.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie at sjchristie@health.ucsd.edu
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
|
|
|
